GSPT1 and astrocytoma (excluding glioblastoma): These results suggest that depletion/deletion of GSPT1 is a novel therapeutic target for astrocyte proliferation-associated diseases, such as astrocytoma, and injury, infarction, and inflammation in the central nervous system.